Salmeterol plus theophylline combination therapy in the treatment of COPD

被引:150
作者
ZuWallack, RL
Mahler, DA
Reilly, D
Church, N
Emmett, A
Rickard, K
Knobil, K
机构
[1] St Francis Hosp & Med Ctr, Sect Pulm Med, Hartford, CT 06105 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[3] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
关键词
chronic bronchitis; combination therapy; COPD; dyspnea; emphysema; exacerbations; FEV1; quality of life;
D O I
10.1378/chest.119.6.1661
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Patients with COPD often require multiple therapies to improve lung function and decrease symptoms and exacerbations. Salmeterol and theophylline are indicated for the treatment of COPD, but the use of these agents in combination has not been extensively studied. Objectives: To compare the efficacy and safety of salmeterol plus theophylline vs either agent alone in COPD, Methods: Randomized, double-blind, double-dummy, parallel-group trial in 943 patients with COPD. lifter an open-label theophylline titration period (serum levels, 10 to 20 mug/mL), patients were randomly assigned to receive salmeterol (42 mug bid) plus theophylline, salmeterol (42 IJ g bid), or theophylline for 12 weeks. Serial pulmonary function tests were completed on day 1 and treatment week 12, Patients kept diary cards and noted their peak flow rates, symptom scores, and albuterol use, and periodically completed quality-of-life and dyspnea questionnaires. Results: All three groups significantly improved compared with baseline. Combination treatment with salmeterol plus theophylline provided significantly (p less than or equal to 0.045) greater improvements in pulmonary function; significantly (p less than or equal to 0.048) greater decreases in symptoms, dyspnea, and albuterol use; and significantly fewer COPD exacerbations (p = 0.023 vs theophylline), In general, treatment with salmeterol provided greater improvement in lung function and satisfaction with treatment compared with theophylline, Salmeterol treatment was also associated with significantly fewer drug-related adverse events (p less than or equal to 0.042) than either treatment that included theophylline, The safety profile (adverse events, vital signs, and ECG findings) of the two treatments that included theophylline were similar. Conclusion: Patients with COPD may benefit from combination treatment with salmeterol plus theophylline without a resulting increase in adverse events or other adverse sequelae.
引用
收藏
页码:1661 / 1670
页数:10
相关论文
共 53 条
[1]   Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro [J].
Anderson, R ;
Feldman, C ;
Theron, AJ ;
Ramafi, G ;
Cole, PJ ;
Wilson, R .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (07) :1387-1394
[2]  
AUBIER M, 1987, CHEST, V92, pS27, DOI 10.1378/chest.92.1.27S
[4]  
Barnes PJ, 2000, CHEST, V117, P10
[5]   Anti-inflammatory effect of β2-agonists:: Inhibition of TNF-α release from human mast cells [J].
Bissonnette, EY ;
Befus, AD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (06) :825-831
[6]   Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells [J].
Bloemen, PGM ;
VandenTweel, MC ;
Henricks, PAJ ;
Engels, F ;
Kester, MHA ;
VandeLoo, PGF ;
Blomjous, FJ ;
Nijkamp, FP .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1997, 272 (04) :L580-L587
[7]  
BONE R, 1994, CHEST, V105, P1411
[8]  
Boyd G, 1997, EUR RESPIR J, V10, P815
[9]   SALMETEROL - A POTENT AND LONG-ACTING INHIBITOR OF INFLAMMATORY MEDIATOR RELEASE FROM HUMAN LUNG [J].
BUTCHERS, PR ;
VARDEY, CJ ;
JOHNSON, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (03) :672-676
[10]   Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease [J].
Cazzola, M ;
Vinciguerra, A ;
Di Perna, F ;
Matera, MG .
RESPIRATORY MEDICINE, 1998, 92 (08) :1012-1016